Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01056393 · ClinicalTrials.gov registry record · Phase 2
Investigator-Sponsored Protocol - Continued Use of Ibalizumab
A Phase 2 study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01056393: Completed Phase 2 study, sponsored by Kaiser Permanente.
NCT01056393 is a Phase 2 study that has completed, run by Kaiser Permanente. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01056393, a Phase 2 study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This protocol serves to extend the successful treatment for HIV positive patients beyond the endpoints provided by the Phase 2b TaiMed Biologics-sponsored protocol TMB202 (entitled "A Phase 2b Randomized, Double-Blinded, 48-Week, Multicenter, Dose-Response Study of Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced Patients Infected with HIV-1 (Amended to 24 Week Study)"), for 24 weeks. Ibalizumab may be administered beyond 24 weeks under this protocol as supply permits and patients continue to demonstrate virologic response.
Interventions
- DRUG ibalizumab 800mg Q2Weeks
- DRUG ibalizumab 2000mg Q4Weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-11 |
| Est. Completion | 2016-12-15 |
| Phase | Phase 2 |
What the finished NCT01056393 record still lists
NCT01056393 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which ibalizumab 800mg Q2Weeks is the first listed.
NCT01056393 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01056393 about?
NCT01056393 is a clinical study titled "Investigator-Sponsored Protocol - Continued Use of Ibalizumab". This protocol serves to extend the successful treatment for HIV positive patients beyond the endpoints provided by the Phase 2b TaiMed Biologics-sponsored protocol TMB202 (entitled "A Phase 2b Randomized, Double-Blinded, 48-Week, Multicenter, Dose-Response Study of Ibalizumab Plus an Optimized Backg...
What is the current status of trial NCT01056393?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2009-11. Estimated completion is 2016-12-15.
What interventions are being tested in trial NCT01056393?
The interventions under investigation include: ibalizumab 800mg Q2Weeks (DRUG), ibalizumab 2000mg Q4Weeks (DRUG).
Who is sponsoring clinical trial NCT01056393?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01056393's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia